Recommended

AstraZeneca boosts production capacity at Texas facility following $445m investment
ESMO 2025: Keytruda immunotherapy shows promise in skin cancer
AstraZeneca research illustrates potential of autonomous UVC disinfection in pharma cleanrooms
Webinar: Radiopharmaceuticals’ time-to-result challenge
Ipsen €1bn ImCheck Therapeutics acquisition deal
Phase III data for next-gen green inhaler push GSK closer to Net Zero targets
Lilly progresses Incyte’s JAK inhibitor in major study
news

Boehringer plans €120m European manufacturing expansion

4
SHARES

The manufacturing capacity for some of Boehringer Ingelheim’s medicines, in disease areas including mental health and cardio-renal-metabolic conditions, will benefit from the European facility expansion.

Boehringer Ingelheim LEO Pharma

Credit: Michael Vi / Shutterstock.com

Using an investment of €120 million, Boehringer Ingelheim is set to expand and upgrade its production site in Koropi, Greece. New technologies at the facility will support the increased manufacturing capacity, the company stated on X. The expansion will boost exports of medicines from Greece to the US market. 

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

This will be the case particularly for Jardiance®, a treatment for type 2 diabetes, chronic heart failure and chronic kidney disease (CKD), according to Boehringer Ingelheim. 

A key producer of innovative medicines: increasing manufacturing capacity

Boehringer Ingelheim’s facility in Koropi is the only industrial facility of a multinational pharmaceutical company in Greece producing innovative medicines, the company acknowledged.

In 2020, the company announced multi-year investments to expand the site and its production capacity.

“We have been present in Greece since 1966, and have gradually expanded our operations in the country… This expansion investment will bring some of our most innovative therapies to an increasing number of patients globally,” affirmed Hubertus von Baumbach, Chairman of the Board of Managing Directors at Boehringer Ingelheim.

At present, the facility has 700 employees, a number that “will increase by more than 100 when this investment is completed,” Greek Prime Minister Kyriakos Mitsotakis highlighted.

Recent developments for Boehringer Ingelheim

Earlier this month, Boehringer Ingelheim agreed a new multi-billion dollar, multi-partner deal, with the intention to develop new RNAi therapeutics for liver diseases. In a statement announcing the partnership, Søren Tullin, PhD, Senior Vice President and Global Head of Cardiometabolic Diseases Research at Boehringer Ingelheim explained that the deal is part of the company’s pledge to help address the interconnected nature of cardiovascular, renal and metabolic diseases.    

Furthermore, to prioritise innovation, Boehringer Ingelheim stated that in 2022, the company’s expenditure was €4.6 billion globally in Human Pharma R&D. A quarter of these net sales were reinvested into research to find new therapies and treatments in disease areas with high unmet needs. Over half of the company’s workforce and over 60 percent of R&D budgets are invested in Europe, it noted.

Share via
Share via